« Return to News | R&D Trends

Almac partners for cancer research in Northern Ireland

Friday, September 6, 2013 02:42 PM

Almac Discovery has announced a $20.2 million partnership with the Center for Cancer Research and Cell Biology (CCRCB) at Queen’s University Belfast (QUB) to accelerate cancer-focused drug discovery in Northern Ireland.

Professor Tim Harrison, Almac’s vice president of Discovery Chemistry, has been appointed inaugural McClay chair of Medicinal Chemistry and will head up the collaborative program.

Almac also has scheduled a phase I clinical trial in ovarian cancer, involving the first novel cancer drug fully developed in Northern Ireland. 

Alan Armstrong, CEO of the Almac Group, said, “By integrating academic and clinical researchers with experienced industrial scientists, we have the means to accelerate cancer focused drug discovery towards the ultimate goal of improving patient care. A team of 17 Almac scientists will be seconded to Queen’s for three years and the combined unit will create a coordinated drug discovery and development pipeline. Resultant products will then continue their development journey with other appropriate partners towards patient-enriched trials and ultimately commercial production. This single-location integrated approach puts the initiative at a distinct advantage and reflects Northern Ireland’s aim to compete more effectively as a modern knowledge-based economy.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.